Preferencias del tratamiento en pacientes con Espondiloartritis axial

D. Capelusnik; E. E. Schneeberger; L. L. Macías Oviedo; J. M. Sevillano Gutiérrez; G. Citera

doi:10.47196/rar.v31i3.392

D. Capelusnik Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Argentina
E. E. Schneeberger Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Argentina
L. L. Macías Oviedo Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Argentina
J. M. Sevillano Gutiérrez Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Argentina
G. Citera Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Argentina

DOI: https://doi.org/10.47196/rar.v31i3.392

Palabras clave: Espondiloartritis axial, tratamiento, preferencias, vía de administración

Resumen

Introducción: una de las premisas del Treat to Target (T2T) es la decisión conjunta del tratamiento entre el reumatólogo y el paciente. Por esta razón las preferencias del paciente juegan un rol fundamental en el éxito del tratamiento a corto y largo plazo. El objetivo de este estudio fue evaluar las preferencias de tratamiento de los pacientes con Espondiloartritis axial (EsPax) e identificar factores asociados a su elección.

Citas

I. Marengo M, Schneeberger E, Citera G, Maldonado Cocco J. Work status among patients with ankylosing spondylitis in Argentina. J Clin Rheumatol 2008;14(5):273-277.

II. Wilson G, Folzenlogen D. Spondyloarthropathies: new directions in etiopathogenesis, diagnosis and treatment. Mo Med 2012;109(1):69-74.

III. Calin A, Elswood J, Riggs S, Skevingtonn S. Ankylosing Spondylitis. An analysis review of 1500 patients. The changing pattern of disease. J Rheumatol 1988;15(8):1234-1238.

IV. Khan M. Update on Spondyloarthropathies. Ann Intern Med 2002;136(12):896907.

V. Braun J, Inman R. Clinical significance of inflammatory back pain for diagnosis and screening of patients with axial spondyloarthrits. Ann Rheum Dis 2010; 69(7):1264-1268.

VI. Rudwaleit M, van Der Heijde D, Landewé R, Listing J, Akkoc N, Bran-dt J, Braun J, et al.: The development of Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009;68(6):777-783.

VII. Saraux F, Guillemin P, Guggenbuhl C, Roux P, Fardellone E, Le Bihan E, et al. Prevalence of spondyloarthropathies in France: 2001. Ann Rheum Dis 2005;64(10):1431-1435.

VIII. De Angelis F, Salaffi W, Grassi W. Prevalence of spondyloarthropathies in an Italian population sample: a regional community-based study. Scand J Rheumatol 2007;36(1):14-21.

IX. Onen F, Akar S, Birlik M, Sari I, Khan M, Gurler O, et al. Prevalence of ankylosing spondylitis and related spondyloarthritides in an urban area of Izmir, Turkey. J Rheumatol 2008;35(2):305-309.

X. van der Heijde D, Ramiro S, Landewé R, Baraliakos X, van den Bosch F, Sepriano A. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 2017;76(6):978-991.

XI. Ward M, Deodhar A, Akl E, Lui A, Ermann J, Gensler L, et al. American College of Rheumatology. Spondylitis Association of Ame-rica. Spondyloarthritis Research and Treatment Network 2015. Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol 2016;68(2):282-298.

XII. Coulter A. Partnerships with patients: the pros and cons of shared clinical decision-making. J Health Serv Res Policy 1997;2(2):112-121.

XIII. Nota I, Drossaert C, Taal E, Vonkeman H, van de Laar M. Patient participation in decisions about disease modifying anti-rheu-matic drugs: a cross-sectional survey. BMC Musculoskelet Disord 2014;15(1):333.

XIV. Vahdat S, Hamzehgardeshi L, Hessam S, Hamzehgardesh Z. Patient Involvement in Health Care Decision Making: A Review. Iran Red Crescent Med J 2014;16(1):12454.

XV. Smolen J, Landewé R, Breedveld F, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69(6):964-975.

XVI. van der Heijde D, Deodhar A, Wei J, Drescher E, Fleishaker D, Hendrikx T, et al. Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, doseranging study. Ann Rheum Dis 2017;76(8):1340-1347.

XVII. Rudwaleit M, van der Heijde D, Landewé R, Listing J, Akkoc N, Bran-dt J, et al. The development of Assessment of Spondyloarthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009;68(6):777-783.

XVIII. van der Heijde D, van ‘t Hof M, van Riel P, Theunisse L, Lubberts E, van Leeuwen MA, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 1990;49(11):916-920.

XIX. van der Heijde D, van ‘t Hof M, van Riel P, Theunisse L, Lubberts E, van Leeuwen MA, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 1990;49(11):916-920.

XX. Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A. Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis 2003;62(2):127-132.

XXI. Citera G, Maldonado Cocco JA, Moroldo M, Burgos-Vargas R, Anaya J, López I, et al. Validación de la versión en español de los cuestionarios de capacidad funcional BASFI y actividad de la enfermedad BASDAI en pacientes con Espondilitis Anquilosante en cuatro países latinoamericanos. Rev Arg Reumatol 1999;10(1):25.

XXII. Doward L, Spoorerg A, Cook S. Development of the ASQoL: a quality of life instrument specific to Ankylosing Spondylitis. Ann Rheum Dis 2003;62(1):20-26.

XXIII. Sommerfleck F, Schneeberger E, Buschiazzo E, Maldonado Cocco J, Citera G. A simplified version of ankylosing spondylitis disease activity score (ASDAS) in patients with ankylosing spondylitis. Clin Rheumatol 2012;31(11):1599-1603.

XXIV. Schneeberger E, Zamora N, Citera G. SASDAS (simplified version of ankylosing spondylitis disease activity score)-ESR performance and development of SASDAS-CRP and their agreement with AS-DAS-ESR and ASDAS-CRP in patients with ankylosing spondylitis. Clin Rheumatol 2016;35(11):2865-2866

XXV. Lukas C, Landewé R, Sieper J, Dougados M, Davis J, Braun J, et al. Development of an ASAS-endorsed disease activity score (AS-DAS) in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68(1):18-24.

XXVI. Nota I, Drossaert C, Taal E, Vonkeman H, van de Laar M. Patient participation in decisions about disease modifying anti-rheumatic drugs: a crosssectional survey. BMC Musculoskelet Disord 2014;15(1):333

XXVII. Nolla J, Rodríguez M, Martín-Mola E, Raya E, Ibero I, Nocea G. Patients’ and rheumatologists’ preferences for the attributes of biological agents used in the treatment of rheumatic diseases in Spain. Patient Prefer Adherence 2016;20(10):1101-1113.

XXVIII. Scalone L, Sarzi-Puttini P, Sinigaglia L, Montecucco C, Giacomelli R, Lapadula G, et al. Patients’, physicians’, nurses’, and pharmacists’ preferences on the characteristics of biologic agents used in the treatment of rheumatic diseases. Patient Prefer Adherence 2018;16(12):2153-2168.

XXIX. Augustovski F, Beratarrechea A, Irazola V, Rubinstein F, Tesolin P, Gonzalez J, et al. Patient preferences for biologic agents in rheumatoid arthritis: a discrete choice experiment. Value Health 2013;16(2):385-393.

XXX. Constantinescu F, Goucher S, Weinstein A, Fraenkel L. Racial disparities in treatment preferences for rheumatoid arthritis. Med Care 2009;47(3):350-355.

XXXI. Constantinescu F, Goucher S, Weinstein A, Smith W, Fraenkel L. Understanding Why Rheumatoid Arthritis Patient Treatment Preferences Differ by Race. Arthritis Rheum 2009;61(4):413-418.

XXXII. Alves Pereira I, Maldonado Cocco J, Feijó Azevedo V, Guerra G, Bautista-Molano W, Casasola J, et al. Levels of satisfaction with rheumatoid arthritis treatment and associated alignment between physicians and patients across Latin America. Clin Rheumatol 2020 Feb 7. doi: 10.1007/s10067-019-04858-x.

XXXIII. Louder A, Singh A, Saverno K, Cappelleri J, Aten A, Koenig A. Patient Preferences Regarding Rheumatoid Arthritis Therapies: A Conjoint Analysis. Am Health Drug Benefits 2016;9(2):84-93.

XXXIV. Taylor P, Betteridge N, Brown T, Woolcott J, Kivitz A, Zerbini C, et al. Treatment mode preferences in rheumatoid arthritis: moving toward shared decision-making. Patient Prefer Adherence 2020;14(1):119-131.

XXXV. Xu Y, Sudharshan L, Hsu MA, Koenig AS, Cappelleri JC, Liu WF, et al. Patient Preferences Associated with Therapies for Psoriatic Arthritis: A Conjoint Analysis. Am Health Drug Benefits 2018;11(8):408-417.

XXXVI. Alten R, Krüger K, Rellecke J, Schiffner-Rohe J, Behmer O, Schiffhorst. Examining patient preferences in the treatment of rheumatoid arthritis using a discrete-choice approach 2016;10(1):2217-2228.

XXXVII. Marshall N, Wilson G, Lapworth K, Kay L. Patients’ perceptions of treatment with anti-TNF therapy for rheumatoid arthritis: a qualitative study. Rheumatology (Oxford) 2004;43(8):1034-1038.

XXXVIII. Williams E, Edwards C. Patient preferences in choosing anti-TNF therapies-R1. Rheumatology (Oxford) 2006;45(12):1575-1576.

XXXIX. Chilton F, Collett R. Treatment choices, preferences and decision making by patients with rheumatoid arthritis. Musculoskeletal Care 2008;6(1):1-14.

XL. Huynh T, Ostergaard A, Egsmose C, Madsen O. Preferences of patients and health professionals for route and frequency of administration of biologic agents in the treatment of rheumatoid arthritis. Patient Prefer Adherence 2014;20(8):93-99.

XLI. Scarpato S, Antivalle M, Favalli E, Nacci F, Frigelli S, Bartoli F, et al. Patient preferences in the choice of anti-TNF therapies in rheumatoid arthritis. Results from a questionnaire survey (RIVIERA study). Rheumatology (Oxford) 2010;49(2):289-294.

XLII. Desplats M, Pascart T, Jelin G, Norberciak L, Philippe P, Houvenagel E, et al. Are abatacept and tocilizumab intravenous users willing to switch for the subcutaneous route of administration? A question-naire-based study. Clin Rheumatol 2017;36(6):1395-1400.

XLIII. Constantinescu F, Goucher S, Weinstein A, Smith W, Fraenkel L. Understanding why rheumatoid arthritis patient treatment preferences differ by race. Arthritis Rheum 2009;61(4):413-418.

XLIV. Li H, Wu L, Jiang N, Yang P, Liu S, Shi X, et al. Treatment satisfaction with rheumatoid arthritis in patients with different disease severity and financial burden: A subgroup analysis of a nationwide survey in China. Chin Med J 2020;133(8):892-898.

XLV. Soriano E, Zazzetti F, Alves Pereira I, Maldonado Cocco J, Feijó Azevedo V, Guerra G, et al. Physician-patient alignment in satisfaction with psoriatic arthritis treatment in Latin America. Clin Rheumatol 2020 Jan 28. doi: 10.1007/s10067-019-04870-1.

XLVI. Furst DE, Tran M, Sullivan E, Pike J, Piercy J, Herrera V, et al. Misalignment between physicians and patient satisfaction with psoriatic arthritis disease control. Clin Rheumatol 2017;36(9):2045-2054.